Agios helps identify genes that allow cancer to escape the immune system

To understand the genetic drivers behind the ability of cancer cells to evade the immune system, scientists at the University of Toronto, in collaboration with Agios Pharmaceuticals, used CRISPR to screen six genetically diverse mouse cancer cell lines. They found that genes involved in autophagy—a process where cells recycle damaged components to regenerate themselves—were key for immune evasion.